Drug:
Reaction: DERMATITIS ATOPIC
20250101 - 20251231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 25114300 |
US |
60 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 302 | 25114307 |
US |
27 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 303 | 25114309 |
US |
25 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 304 | 25114331 |
US |
41 | 2 |
Mastocytosis, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 305 | 25114332 |
US |
37 | 1 |
Dermatitis atopic, Rash macular, |
||||
DUPILUMAB, |
||||
| 306 | 25114369 |
US |
21 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 307 | 25114388 |
US |
62 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 308 | 25114402 |
US |
3 | 2 |
Dermatitis atopic, Skin ulcer, |
||||
DUPILUMAB, |
||||
| 309 | 25114427 |
US |
60 | 2 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 310 | 25114430 |
US |
59 | 1 |
Dermatitis atopic, Eczema, |
||||
DUPILUMAB, |
||||
| 311 | 25114467 |
US |
1 | |
Pruritus, Surgery, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 312 | 25114469 |
US |
45 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 313 | 25114481 |
US |
38 | 1 |
Abdominal discomfort, Dermatitis atopic, Blister, Pain, Condition aggravated, |
||||
DUPILUMAB, |
||||
| 314 | 25114494 |
US |
2 | |
Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, RIZATRIPTAN, |
||||
| 315 | 25114496 |
US |
35 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 316 | 25114502 |
US |
71 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 317 | 25114509 |
US |
38 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 318 | 25114522 |
US |
17 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 319 | 25114534 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 320 | 25114547 |
US |
26 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 321 | 25114549 |
US |
1 | |
Sensitivity to weather change, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 322 | 25114560 |
US |
58 | 1 |
Pruritus, Rash, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 323 | 25114583 |
US |
1 | |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 324 | 25114615 |
US |
23 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 325 | 25114619 |
US |
11 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 326 | 25114620 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 327 | 25114627 |
US |
12 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 328 | 25115166 |
US |
75 | 1 |
Dermatitis atopic, Rash macular, |
||||
DUPILUMAB, NINTEDANIB, |
||||
| 329 | 25115240 |
US |
49 | 1 |
Dermatitis atopic, Skin swelling, Dry skin, Erythema, Pruritus, |
||||
DUPILUMAB, |
||||
| 330 | 25115355 |
US |
42 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 331 | 25109164 |
US |
1 | |
Weight increased, Dermatitis atopic, Pruritus, Scratch, |
||||
DUPILUMAB, |
||||
| 332 | 25109166 |
US |
13 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 333 | 25109191 |
US |
47 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 334 | 25109197 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 335 | 25109201 |
US |
67 | 1 |
Injection site pain, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 336 | 25109216 |
US |
31 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 337 | 25109225 |
US |
3 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 338 | 25109241 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 339 | 25109246 |
US |
55 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 340 | 25109263 |
US |
2 | |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 341 | 25109272 |
US |
43 | 2 |
Sensitivity to weather change, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, LEVONORGESTREL, |
||||
| 342 | 25109297 |
US |
2 | |
Eye irritation, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 343 | 25109299 |
US |
35 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 344 | 25109310 |
US |
14 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 345 | 25109334 |
US |
37 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 346 | 25109356 |
US |
20 | 1 |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 347 | 25109357 |
US |
33 | 2 |
Dermatitis atopic, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 348 | 25109388 |
US |
19 | 2 |
Injection site bruising, Dermatitis atopic, Pruritus, Dry skin, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 349 | 25109438 |
US |
2 | |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 350 | 25109440 |
US |
43 | 2 |
Dermatitis atopic, Product use in unapproved indication, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 351 | 25109482 |
US |
22 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 352 | 25109554 |
US |
17 | 2 |
Dermatitis atopic, Intentional product misuse, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 353 | 25109671 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 354 | 25107647 |
AR |
63 | 1 |
Retinal detachment, Dermatitis atopic, Breast induration, |
||||
UPADACITINIB, |
||||
| 355 | 25107735 |
US |
1 | |
Weight increased, Dermatitis atopic, |
||||
UPADACITINIB, |
||||
| 356 | 25107785 |
US |
38 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 357 | 25107799 |
US |
67 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 358 | 25107810 |
US |
40 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 359 | 25107811 |
US |
3 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 360 | 25107820 |
US |
38 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 361 | 25107825 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 362 | 25107833 |
US |
1 | |
Dermatitis atopic, Rash erythematous, |
||||
DUPILUMAB, |
||||
| 363 | 25107835 |
US |
30 | 2 |
Rash, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 364 | 25107837 |
US |
18 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 365 | 25107859 |
US |
37 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 366 | 25107864 |
US |
2 | |
Dermatitis atopic, Rash erythematous, Condition aggravated, Urticaria, |
||||
DUPILUMAB, |
||||
| 367 | 25107868 |
US |
58 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 368 | 25107869 |
US |
3 | 1 |
Sleep disorder due to a general medical condition, Dermatitis atopic, Pruritus, Dry skin, |
||||
DUPILUMAB, |
||||
| 369 | 25107870 |
US |
71 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 370 | 25107872 |
US |
44 | 1 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 371 | 25107876 |
US |
18 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 372 | 25107882 |
US |
16 | 2 |
Dermatitis atopic, Product dose omission issue, Needle issue, |
||||
DUPILUMAB, |
||||
| 373 | 25107885 |
US |
56 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 374 | 25107887 |
US |
28 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 375 | 25107891 |
US |
39 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 376 | 25107892 |
US |
46 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 377 | 25107898 |
US |
27 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 378 | 25107944 |
US |
77 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 379 | 25107947 |
US |
18 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 380 | 25107951 |
US |
32 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 381 | 25107955 |
US |
26 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 382 | 25107961 |
US |
64 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 383 | 25107968 |
US |
55 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 384 | 25107978 |
US |
15 | 2 |
Dermatitis atopic, Rash, Pruritus, Product dose omission in error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 385 | 25107985 |
US |
40 | 2 |
COVID-19, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 386 | 25107988 |
US |
16 | 2 |
Injection site swelling, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 387 | 25107995 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 388 | 25108005 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 389 | 25108008 |
US |
27 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 390 | 25108011 |
US |
47 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 391 | 25108016 |
US |
58 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, RISANKIZUMAB-RZAA, |
||||
| 392 | 25108017 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 393 | 25108027 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 394 | 25108029 |
US |
48 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 395 | 25108042 |
US |
50 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 396 | 25108067 |
US |
32 | 2 |
Dermatitis atopic, Pruritus, Dry skin, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 397 | 25108073 |
US |
67 | 2 |
Dermatitis atopic, Stress, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 398 | 25108093 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 399 | 25108094 |
US |
43 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 400 | 25108106 |
US |
40 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28